Evidence map›Paper›PMID 41704748›Full record

ReviewiScience2026

Cancer-associated fibroblasts as a critical driver in tumor metastasis: The mechanisms and future perspectives.

Lingyu Ding, Zhen Li, Jing Yue, Liqing Qiu, Zhifeng Tian, Hongfang Zhang

Abstract readReview
In one paragraph

Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lingyu DingDepartment of Medical Oncology, Hangzhou Cancer Hospital, Hangzhou 310002, China.
Zhen LiThe Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Jing YueHangzhou Cancer Institution, Hangzhou Cancer Hospital, Hangzhou 310002, China.
Liqing QiuHangzhou Cancer Institution, Hangzhou Cancer Hospital, Hangzhou 310002, China.
Zhifeng TianDepartment of Oncology Center, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China.
Hongfang ZhangHangzhou Cancer Institution, Hangzhou Cancer Hospital, Hangzhou 310002, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor metastasis represents a lethal event for patients due to the lack of effective treatments. Compared with primary tumors, the components of the tumor microenvironment (TME) of metastatic tumors are different. Tumor cells alone are unable to metastasize. Cancer-associated fibroblasts (CAFs), as one major component of TME, drive tumor metastasis. In metastatic lesions, the proportion of CAFs is significantly higher and is spatially close to tumor cells with high metastatic potential. CAFs themselves are resistant to chemoradiotherapy and have strong invasive ability based on their major role in degrading the extracellular matrix (ECM). Furthermore, CAFs determined the organs to which tumor cells metastasize. By interaction with tumor cells, CAFs were activated, transdifferentiated, and in turn enhanced the invasive ability of tumor cells. Tumor cells also promoted the infiltration of CAFs in tumor tissues, allowing them to establish a pre-metastatic microenvironment. In this review, we have deeply analyzed the association of CAFs and tumor metastasis from the perspectives of exosomes, metabolic reprogramming, suppression of anti-tumor immunity, and epigenetic modification. We also discussed the future perspectives of CAFs-based anti-metastasis strategies. This information may deepen our understanding of CAFs-initiated tumor metastasis and shed novel insight into the development of anti-metastasis therapies.

Indexed as

CancerMicroenvironment

Identifiers

PMID41704748
PMCPMC12907831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.